Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
Saved in:
| Title: | Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. |
|---|---|
| Authors: | Westhovens R; Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Flanders, Belgium rene.westhovens@uzleuven.be.; Division of Rheumatology, University Hospitals KU Leuven, Leuven, Flanders, Belgium., Rigby WFC; Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA., van der Heijde D; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Ching DWT; Timaru Medical Specialists Limited, Timaru, New Zealand., Stohl W; University of Southern California Keck School of Medicine, Los Angeles, California, USA., Kay J; Division of Rheumatology, Department of Medicine, UMass Memorial Medical Center, Worcester, Massachusetts, USA.; Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA., Chopra A; Centre for Rheumatic Diseases, Pune, India., Bartok B; Gilead Sciences, Foster City, California, USA., Matzkies F; Gilead Sciences, Foster City, California, USA., Yin Z; Gilead Sciences, Foster City, California, USA., Guo Y; Gilead Sciences, Foster City, California, USA., Tasset C; Galapagos NV, Mechelen, Belgium., Sundy JS; Gilead Sciences, Foster City, California, USA.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Jahreis A; Gilead Sciences, Foster City, California, USA., Mozaffarian N; Ichnos Sciences, New York, New York, USA., Messina OD; Cosme Argerich Hospital, Buenos Aires, Argentina.; Investigaciones Reumatologicas y Osteologicas SRL IRO, Buenos Aires, Argentina., Landewé RB; Department of Rheumatology & Clinical Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands.; Department of Rheumatology, Zuyderland Hospital, Heerlen, The Netherlands., Atsumi T; Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Burmester GR; Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany.; Free University and Humboldt University, Berlin, Germany. |
| Source: | Annals of the rheumatic diseases [Ann Rheum Dis] 2021 Jun; Vol. 80 (6), pp. 727-738. Date of Electronic Publication: 2021 Jan 15. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic) Linking ISSN: 00034967 NLM ISO Abbreviation: Ann Rheum Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
